JETEMA, Co., Ltd. (216080.KQ)
KRW 15130.0
(-2.64%)
KRW 15130.0
(-2.64%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 11 Billion KRW | 40.21% |
| 2022 | 16.89 Billion KRW | 39.03% |
| 2021 | 17.93 Billion KRW | 325.0% |
| 2020 | -5.1 Billion KRW | 72.49% |
| 2019 | -9.12 Billion KRW | -151.74% |
| 2018 | -13.5 Billion KRW | -13.23% |
| 2017 | -3.63 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 4.41 Billion KRW | 9.59% |
| 2024 Q1 | 4.03 Billion KRW | -77.85% |
| 2023 Q1 | 3.05 Billion KRW | 40.66% |
| 2023 Q3 | 2.59 Billion KRW | -14.42% |
| 2023 Q2 | 3.03 Billion KRW | -0.72% |
| 2023 FY | - KRW | 40.21% |
| 2023 Q4 | 2.32 Billion KRW | -10.6% |
| 2022 Q2 | 2.3 Billion KRW | 106.73% |
| 2022 Q1 | 1.11 Billion KRW | -56.61% |
| 2022 Q3 | 2.25 Billion KRW | -2.16% |
| 2022 FY | - KRW | 39.03% |
| 2022 Q4 | 2.17 Billion KRW | -3.71% |
| 2021 Q3 | -350.94 Million KRW | -120.88% |
| 2021 Q4 | 2.57 Billion KRW | 832.66% |
| 2021 Q1 | 1.74 Billion KRW | -13.08% |
| 2021 FY | - KRW | 325.0% |
| 2021 Q2 | 1.68 Billion KRW | -3.73% |
| 2020 Q3 | -1 Billion KRW | 28.68% |
| 2020 Q1 | -2.11 Billion KRW | 33.64% |
| 2020 FY | - KRW | 72.49% |
| 2020 Q4 | 2 Billion KRW | 300.37% |
| 2020 Q2 | -1.4 Billion KRW | 33.41% |
| 2019 Q3 | -2.35 Billion KRW | 0.0% |
| 2019 FY | - KRW | -151.74% |
| 2019 Q4 | -3.18 Billion KRW | -35.27% |
| 2019 Q1 | -2.44 Billion KRW | 0.0% |
| 2018 Q1 | -332.95 Million KRW | 0.0% |
| 2018 FY | - KRW | -13.23% |
| 2017 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Co., Ltd. | -172.27 Billion KRW | 106.39% |
| iNtRON Biotechnology, Inc. | -6.23 Billion KRW | 276.558% |
| BINEX Co., Ltd. | 10.87 Billion KRW | -1.248% |
| Bioneer Corporation | 10.04 Billion KRW | -9.604% |
| Anterogen.Co.,Ltd. | -437.82 Million KRW | 2614.195% |
| MEDIPOST Co., Ltd. | -19.39 Billion KRW | 156.765% |
| CrystalGenomics, Inc. | -42.79 Billion KRW | 125.721% |
| Helixmith Co., Ltd | -53 Billion KRW | 120.768% |
| Chabiotech Co.,Ltd. | 70.08 Billion KRW | 84.294% |
| Medy-Tox Inc. | 32.69 Billion KRW | 66.335% |
| Peptron, Inc. | -12.65 Billion KRW | 187.014% |
| Amicogen, Inc. | 13.95 Billion KRW | 21.109% |
| Genexine, Inc. | -40.87 Billion KRW | 126.928% |
| HLB Therapeutics Co.,Ltd. | 8.22 Billion KRW | -33.758% |
| LegoChem Biosciences, Inc. | -71.38 Billion KRW | 115.42% |
| ALTEOGEN Inc. | 440.04 Million KRW | -2401.526% |
| PharmaResearch Co., Ltd. | 104.25 Billion KRW | 89.441% |
| SillaJen, Inc. | -17.35 Billion KRW | 163.436% |
| OliX Pharmaceuticals,Inc | -11.13 Billion KRW | 198.857% |
| Genomictree Inc. | -6.33 Billion KRW | 273.848% |
| MedPacto, Inc. | -32.6 Billion KRW | 133.757% |
| D&D Pharmatech | -9.05 Billion KRW | 221.527% |
| EASY BIO,Inc. | 24.32 Billion KRW | 54.744% |
| GI Innovation, Inc. | -51.33 Billion KRW | 121.445% |